Aurinia Pharmaceuticals/$AUPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Ticker
$AUPH
Sector
Primary listing
Industry
Biotechnology
Headquarters
Edmonton, Canada
Employees
130
ISIN
CA05156V1022
Website
AUPH Metrics
BasicAdvanced
$1.1B
30.26
$0.27
1.17
-
Price and volume
Market cap
$1.1B
Beta
1.17
52-week high
$9.98
52-week low
$5.20
Average daily volume
1.3M
Financial strength
Current ratio
5.932
Quick ratio
5.162
Long term debt to equity
17.809
Total debt to equity
22.248
Interest coverage (TTM)
9.19%
Profitability
EBITDA (TTM)
61.923
Gross margin (TTM)
79.76%
Net profit margin (TTM)
16.11%
Operating margin (TTM)
17.17%
Effective tax rate (TTM)
4.69%
Revenue per employee (TTM)
$1,900,000
Management effectiveness
Return on assets (TTM)
5.20%
Return on equity (TTM)
11.23%
Valuation
Price to earnings (TTM)
30.258
Price to revenue (TTM)
4.615
Price to book
3.17
Price to tangible book (TTM)
3.2
Price to free cash flow (TTM)
17.834
Free cash flow yield (TTM)
5.61%
Free cash flow per share (TTM)
45.14%
Growth
Revenue change (TTM)
29.20%
Earnings per share change (TTM)
-161.06%
3-year revenue growth (CAGR)
55.07%
10-year revenue growth (CAGR)
97.56%
3-year earnings per share growth (CAGR)
-40.61%
10-year earnings per share growth (CAGR)
-9.69%
What the Analysts think about AUPH
Analyst ratings (Buy, Hold, Sell) for Aurinia Pharmaceuticals stock.
Bulls say / Bears say
Aurinia Pharmaceuticals reported a 24% increase in total net revenue for Q3 2024, reaching $67.8 million, driven by a 36% growth in net product revenue from LUPKYNIS sales. (businesswire.com)
The company achieved a net income of $14.4 million in Q3 2024, a significant turnaround from a net loss of $13.4 million in the same period of 2023, indicating improved financial health. (businesswire.com)
Aurinia's strategic restructuring, including a 25% reduction in workforce and discontinuation of the AUR300 program, is expected to yield annual cost savings of $50 to $55 million, enhancing operational efficiency. (businesswire.com)
Despite increased revenues, Aurinia's gross margin declined to 87% for the nine months ended September 30, 2024, down from 93% in the same period of 2023, potentially indicating rising production costs. (businesswire.com)
The company's cash, cash equivalents, and investments decreased slightly to $348.7 million as of September 30, 2024, from $350.7 million at the end of 2023, which may raise concerns about cash flow sustainability. (businesswire.com)
The restructuring efforts, while aimed at cost savings, resulted in one-time charges of approximately $11 to $15 million, which could impact short-term financial performance. (businesswire.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
AUPH Financial Performance
Revenues and expenses
AUPH Earnings Performance
Company profitability
AUPH News
AllArticlesVideos
New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis
Business Wire·1 month ago
Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance
Benzinga·1 month ago
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aurinia Pharmaceuticals stock?
Aurinia Pharmaceuticals (AUPH) has a market cap of $1.1B as of June 25, 2025.
What is the P/E ratio for Aurinia Pharmaceuticals stock?
The price to earnings (P/E) ratio for Aurinia Pharmaceuticals (AUPH) stock is 30.26 as of June 25, 2025.
Does Aurinia Pharmaceuticals stock pay dividends?
No, Aurinia Pharmaceuticals (AUPH) stock does not pay dividends to its shareholders as of June 25, 2025.
When is the next Aurinia Pharmaceuticals dividend payment date?
Aurinia Pharmaceuticals (AUPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals (AUPH) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.